T-cell receptor anti-CMV CDR3s from bone marrow samples are associated with a worse overall survival for recurrent acute myeloid leukemia.

Srijit Paul, Michael T Aboujaoude, Vayda R Barker, Tabitha R Hudock, Arpan Sahoo, George Blanck

Abstract read

In one paragraph

Article in Leukemia research reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Srijit PaulDepartment of Molecular Medicine Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA.

Michael T AboujaoudeDepartment of Molecular Medicine Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA.

Vayda R BarkerDepartment of Molecular Medicine Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA.

Tabitha R HudockDepartment of Molecular Medicine Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA.

Arpan SahooDepartment of Molecular Medicine Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA.

George BlanckDepartment of Molecular Medicine Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We assessed the relationship of AML patient outcomes and T-cell receptor (TCR) recombination reads representing known anti-viral TCR sequences. TCR complementary determining region-3's (CDR3s) were obtained from the pediatric TARGET-AML dataset, and the TCR CDR3s representing bone marrow samples of primary and recurrent disease were matched to anti-viral TCR CDR3s. The patients representing the presence of the anti-viral CDR3s were then assessed for overall survival (OS). Patients with anti-CMV TCR CDR3s from bone marrow samples representing recurrent AML showed a significant decrease in OS probability. Decreases in OS probabilities were also observed for patients with anti-Epstein Barr Virus (EBV) TCR CDR3s obtained from recurrent AML, bone marrow samples. Overall, this study raises the question of whether there is a relationship between viral infections, or the basic impact of anti-viral inflammation, and outcomes in pediatric AML?

Indexed as

Acute myeloid leukemiaAnti-viral complementarity determining region-3CMVCo-morbiditiesT-cell receptor

Identifiers

PMID41908976

DOI10.1016/j.lrr.2026.100580

PMCPMC13019061

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.